Skip to main content

Help patients save on their prescription

Many patients pay as little as $30

No generic equivalent available

To redeem, instruct patients to:

  • Go to BREXAFEMME.com and print the BREXAFEMME Savings Card or text “SAVE” to “BREXA”* (27392)
  • Bring their prescription for BREXAFEMME and the print-out of the BREXAFEMME Savings Card to the pharmacy
  • Commercial insurance patients may pay as little as $30
  • Cash-paying patients may pay as little as $120

Provide BREXAFEMME Savings
Offer details to your patients

Have questions? We can help. Call 1-844-431-9894.

Patients pay as little as $30

BREXAFEMME® (ibrexafungerp, 150 mg per tablet) product shot with blister pack

Message and data rates apply. 1 message per request. Reply "HELP" for help and "STOP" to stop.

TERMS AND CONDITIONS

To Patients: Offer valid for eligible commercially-insured and cash-paying patients with a prescription for BREXAFEMME® (Ibrexafungerp) including a valid Prescriber ID#. If eligible, you may pay as little as $30, and the card will pay up to the maximum benefit. If cash-paying, you may pay as little as $120, and the card will pay up to the maximum benefit. For questions about the BREXAFEMME Savings Card call 1-844-431-9894.

To Pharmacists: By using this offer, you certify you have not submitted a claim for reimbursement of this Rx with any federal, state, or other government program. Participation must comply with all relevant laws and regulations as a pharmacy provider, and must comply with the terms and conditions below.

Pharmacist instructions for a patient with an Eligible Third Party: Submit claim to the primary Third Party Payer first, then submit balance due to Change Healthcare (as a Secondary Payer; copay-only billing using valid Other Coverage Code (e.g. 8, 3)). The patient may pay as little as $30, and the card will pay up to the maximum benefit. Reimbursement comes directly from Change Healthcare.

Pharmacist instructions for a cash-paying patient: Submit claim to Change Healthcare. Include valid Other Coverage Code (e.g. 0, 1). The card will pay up to the maximum benefit. After the offer is applied, the patient will be responsible for any remaining balance due. Reimbursement comes directly from Change Healthcare. For questions with processing, call the Change Healthcare help desk at 1-800-433-4893.

Terms and Conditions: Offer valid only in the United States. Offer not valid for those enrolled in Medicare, Medicaid, TRICARE or any other federal or state healthcare plan. If you are enrolled in a state or federal healthcare plan, you may not use this Savings Card (even if you elect to be processed as an uninsured/cash-paying patient). Offer will be accepted at participating pharmacies only. This offer is not health insurance.

By using this offer you agree to comply with terms of your health insurance contract which may require you to tell your insurer about the offer. It is illegal to sell (or offer to), purchase, or trade this offer. Offer is not transferable. Valid for one prescription. Not valid if reproduced. Void where prohibited by law. SCYNEXIS Inc., reserves the right to rescind, revoke, or amend this offer without notice at any time.

Indication

BREXAFEMME® is a triterpenoid antifungal indicated for the treatment of adult and postmenarchal pediatric females with vulvovaginal candidiasis (VVC).

Important Safety Information

  • BREXAFEMME is contraindicated during pregnancy and in patients with a history of hypersensitivity to ibrexafungerp
  • BREXAFEMME administration during pregnancy may cause fetal harm based on animal studies. Prior to initiating treatment, verify pregnancy status in females of reproductive potential and advise them to use effective contraception during treatment
  • When administering BREXAFEMME with strong CYP3A inhibitors, the dose of BREXAFEMME should be reduced to 150 mg twice a day for one day. Administration of BREXAFEMME with strong CYP3A inducers should be avoided
  • Most common adverse reactions observed in clinical trials (incidence ≥2%) were diarrhea, nausea, abdominal pain, dizziness, and vomiting

To report SUSPECTED ADVERSE REACTIONS, contact SCYNEXIS, Inc. at 1-888-982-SCYX (1-888-982-7299) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

To report SUSPECTED ADVERSE REACTIONS, contact SCYNEXIS, Inc. at 1-888-982-SCYX (1-888-982-7299) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see full Prescribing Information and Patient Information.

References: 1. BREXAFEMME. Prescribing Information. SCYNEXIS, Inc.; 2021. 2. Scynexis, Inc. Updated June 2, 2021. Accessed July 2, 2021. https://www.scynexis.com/news-media/press-releases/detail/240/scynexis-announces-fda-approval-of-brexafemme. 3. Pappas PG, Kauffman CA, Andes DR, et al. Clinical Practice Guideline for the management of candidiasis: 2016 Update by the Infectious Diseases Society of America. Clin Infec Dis. 2016;62(4):e1–50. 4. Gintjee TJ, Donnelley MA, Thompson GR 3 rd . Aspiring antifungal: review of current antifungal pipeline developments. J Fungi (Basel). 2020:6(1):28 doi:10.3390/jof601028. 5. Data on file [1]. SCYNEXIS, Inc., Jersey City, NJ. 6. Data on file [2]. SCYNEXIS, Inc., Jersey City, NJ. 7. Data on file [3]. SCYNEXIS, Inc., Jersey City. NJ. 8. Data on file [4]. SCYNEXIS, Inc., Jersey City. NJ.

Important Safety Information

Indication

  • BREXAFEMME is contraindicated during pregnancy and in patients with a history of hypersensitivity to ibrexafungerp
  • BREXAFEMME administration during pregnancy may cause fetal harm based on animal studies. Prior to initiating treatment, verify pregnancy status in females of reproductive potential and advise them to use effective contraception during treatment
  • When administering BREXAFEMME with strong CYP3A inhibitors, the dose of BREXAFEMME should be reduced to 150 mg twice a day for one day. Administration of BREXAFEMME with strong CYP3A inducers should be avoided
  • Most common adverse reactions observed in clinical trials (incidence ≥2%) were diarrhea, nausea, abdominal pain, dizziness, and vomiting

To report SUSPECTED ADVERSE REACTIONS, contact SCYNEXIS, Inc. at 1-888-982-SCYX (1-888-982-7299) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

To report SUSPECTED ADVERSE REACTIONS, contact SCYNEXIS, Inc. at 1-888-982-SCYX (1-888-982-7299) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see full Prescribing Information and Patient Information.

BREXAFEMME® is a triterpenoid antifungal indicated for the treatment of adult and postmenarchal pediatric females with vulvovaginal candidiasis (VVC).